ANOTHER SIGN OF HEALTHCARE’S TRANSFORMATION came on June 1 when Sysmex Corporation of Kobe, Japan, and Laboratory Corporation of America in Burlington, North Carolina, announced a unique collaboration to develop blood-based molecular diagnostic tests for cancer.
The collaboration calls for Sysmex, a major in vitro diagnostics (IVD) manufacturer with expertise in hematology testing, to work with LabCorp. Efforts will center around two assays developed at Sysmex Inostics, called OncoBEAM and Plasma-Sequencing.
- IVD Market Update
LabCorp, Sysmex Will Collaborate To Develop Liquid Biopsy Tests
NeoGenomics announces 12 assays with liquid biopsy technology to detect tumors, monitor patients’ response
- By Robert Michel
- | From the Volume XXII NO. 9 - June 22, 2015 Issue
